Rubicon Research Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹576 Cr +39.8% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
RR

Rubicon Research

Q3 FY26Pharmaceuticals & Biotechnology

Rubicon Research Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹476Cr
+52.1% YoY
+15.5% QoQ
Net profit
₹73Cr
+92.1% YoY
+35.2% QoQ
Margin
23%
+1 pp YoY
0 pp QoQ
Price₹1,725
Market cap₹28.5K Cr
P/E99.1

The short version

The company remains confident in a strong growth trajectory with broad-based revenue growth across both new launches and existing products.

From Rubicon Research's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company remains confident in a strong growth trajectory with broad-based revenue growth across both new launches and existing products.
  • Specialty portfolio contribution to gross profit has increased from around 27% to about 31-32%, and is expected to continue growing.
  • R&D productivity has improved (from 3.3x to 5.7x revenue multiple over R&D spend), supporting sustainable incremental revenue growth.
  • The ramp-up of the Pithampur manufacturing facility in CY 2026 - early CY 2027 is expected to aid capacity, supporting revenue growth.

2 more points from Rubicon Research's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Rubicon Research said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company acquired the Pithampur manufacturing facility in June 2025 to build more capacity and capabilities, including high potent oncology, hormones, and steroids, with room for expansion.
  • Pithampur is on track for operationalization and validation completion by mid-2026 and expected commercialization by Q1 CY 2027.
  • Additional capex of around INR 70 crores was made alongside the Pithampur acquisition.
  • The company holds a cash reserve of INR 334 crores, providing "dry powder" for inorganic growth aspirations.
  • Evaluations and tactical measures regarding own manufacturing versus outsourcing to optimize margins are ongoing.

2 more points from Rubicon Research's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rubicon Research said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Rubicon Research said on order book & pipeline — free account, 30 seconds.

Rubicon Research — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Rubicon Research Q3 FY26 results — key figures

Rubicon Research Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue476313+52.1%412+15.5%
Operating profit (EBITDA)10870+54.3%94+14.9%
Operating margin23%22%+1 pp23%0 pp
Profit before tax9153+71.7%72+26.4%
Net profit (PAT)7338+92.1%54+35.2%
EPS (₹)4.422.50+76.8%3.49+26.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹576 Cr, net profit ₹90 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Rubicon Research and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Rubicon Research Q3 FY26 results?

The company remains confident in a strong growth trajectory with broad-based revenue growth across both new launches and existing products.

What is Rubicon Research share price analysis?

Rubicon Research currently shows a neutral. The stock trades at a P/E of 99.0 with a market cap of ₹28,549 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rubicon Research planning capital expenditure?

The company acquired the Pithampur manufacturing facility in June 2025 to build more capacity and capabilities, including high potent oncology, hormones, and steroids, with room for expansion.

Keep Rubicon Research on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.